The European Society for Medical Oncology (ESMO) held its 2018 Congress in Munich, Germany, from October 19 to 23. There, experts in the cancer community from around the world gathered to share and discuss ways to improve patient care and access to high-quality care.
In this podcast, Brian I. Rini, MD, and Jorge A. Garcia, MD, talk about the treatment landscape for kidney and prostate cancers and some of the research highlights from this meeting that involve these 2 genitourinary (GU) cancers.
Combining axitinib (Inlyta), a targeted therapy, and avelumab (Bavencio), an immunotherapy, to treat metastatic kidney cancer [3:11].
Combining atezolizumab (Tecentriq) and bevacizumab (Avastin) to treat kidney cancer [7:04].
The possibility of using immunotherapy to treat sarcomatoid kidney tumors [9:34].
The current understanding of the treatment of metastatic prostate cancer [11:47]
New data for the treatment of low-volume metastatic prostate cancer [16:52]
What happens when abiraterone acetate (Zytiga) is combined with radium-223 to treat advanced castration-resistant prostate cancer [19:23]
Dr. Rini is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is the Lineagotica Associate Editor for Genitourinary Cancers. Dr. Garcia is an Assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Garcia is the Lineagotica Specialty Editor for Genitourinary Cancers. Both Dr. Rini and Dr. Garcia are staff members of the Department of Solid Tumor Oncology at Cleveland Clinic Taussig Cancer Institute.
Was this podcast useful? Please subscribe, rate, and review Lineagotica Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Lineagotica podcast page.